A Phase 2 interventional study of Bevacizumab and nasal electrocoagulation. in Bevacizimab and HHT, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Clinical Study Abstract (Ethics Application) Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant vascular disorder characterized by recurrent intractable epistaxis and multi-organ arteriovenous malformations. Moderate-to-severe patients often develop refractory anemia with severely impaired quality of life. Current stepwise therapeutic strategies have substantial limitations, including frequent adverse reactions of thalidomide, high recurrence rates after electrocoagulation, and severe surgical trauma, resulting in a lack of safe and individualized treatment options. Our preliminary clinical practice has verified the promising efficacy and long-term benefits of bevacizumab in severe HHT-related epistaxis. However, obvious interindividual variability and occasional adverse events exist, and the underlying mechanism remains unclear. This study aims to systematically evaluate the efficacy and safety of bevacizumab for severe HHT-associated epistaxis, explore the influences of baseline clinical and genetic factors on prognosis, and investigate the mechanism of treatment heterogeneity, so as to optimize individualized therapeutic strategies and provide clinical evidence for precise management of HHT in China.
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis (Curaçao criteria)
Patients who meet at least 3 of the following 4 items are diagnosed with definite HHT:
Spontaneous, recurrent epistaxis Multiple mucocutaneous telangiectasias at typical sites Visceral arteriovenous malformations (lung, liver, brain, gastrointestinal tract, etc.) Positive family history of HHT in a first-degree relative Genetic diagnosis Identification of a pathogenic germline mutation in HHT-associated genes (ENG, ACVRL1) confirms the diagnosis of HHT.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
surgery combined with intravenous injection of bevacizumab
Drug: Bevacizumab · Procedure: nasal electrocoagulation.
Surgery combined with oral thalidomide
Procedure: nasal electrocoagulation. · Drug: Thalidomide (50mg)
Bevacizumab is administered intravenously at 5 mg/kg body weight, 1 to 2 times annually, starting one month after nasal electrocoagulation.
nasal electrocoagulation.
Oral thalidomide is initiated at 50 mg twice daily (100 mg per day) one month after nasal electrocoagulation.
ESS
Epistaxis Severity Score
Time frame: 1,3.6.12 months after surgery
Hb
Hemoglobin (Hb)
Time frame: 1,3,6,12months after surgery
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Sep 2029, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab
Second Affiliated Hospital, Zhejiang University, School of Medicine →